MGTA News and Press, Magenta Therapeutics Inc. From 07/21/21

Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patie...

Magenta Therapeutics (MGTA) announces the appointment of Caren Deardorf as the company’s chief commercial officer.Deardorf has more than 25 years of international biotechnology leadership experience across a range of therapeutic areas.She comes to Magenta from Ohana...

Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company’s first Chief Commercial Of...

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

The following slide deck was published by Magenta Therapeutics, Inc. in conjunction with this event. For further details see: Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow

marchmeena29/iStock via Getty Images AstraZeneca bullish on Enhertu in upcoming studies BofA Securities talked with AstraZeneca (AZN) EVP, Oncology Dave Frederick who told the firm the company believes two upcoming studies on Enhertu (fam-trastuzumab deruxtecan-nxki) will boost use of the bre...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer. “We welcome Tom ...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

– Preliminary results from the initial cohort of 10 patients were previously reported on May 12 in a published abstract at the European Hematology Association (EHA) Congress – – The cumulative data as of the data cut-off date show that all patients (15/15)...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual ...